Iovance Biotherapeutics, Inc. Stock Deutsche Boerse AG
Stocks
2LB
US4622601007
Biotechnology & Medical Research
|
Real-time Estimate
Tradegate
13:37:20 2026-09-18 EDT
|
5-day change | 1st Jan Change | ||
| 8.730 EUR | -4.28% |
|
+26.20% | +270.43% |
| 08-20 | Iovance's Growth Outlook Clouded as Amtagvi Faces Competition Hurdles, UBS Says | MT |
| 08-20 | UBS Adjusts Iovance Biotherapeutics Price Target to $7 From $4, Maintains Neutral Rating | MT |
| Market Cap | 4.54B 3.96B 3.74B 3.39B 6.36B 436B 6.38B 44.76B 17.27B 221B 17.05B 16.67B 712B | P/E 2026 * |
-21x | P/E 2027 * | -41.4x |
|---|---|---|---|---|---|
| Enterprise Value | 4.27B 3.73B 3.52B 3.2B 5.99B 410B 6.01B 42.16B 16.27B 209B 16.06B 15.7B 671B | EV / Sales 2026 * |
10.6x | EV / Sales 2027 * | 7.65x |
| Free-Float |
99.65% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| IOVA | Delayed | |
CBOE
| IOVA | Real-time | |
|
Tradegate
| 2LB | Real-time | |
|
London S.E.
| 0JDK | Delayed | |
|
Boerse Muenchen
| 2LB | Real-time | |
|
Deutsche Boerse AG
| 2LB | Delayed | |
|
Börse Stuttgart
| 2LB | Delayed | |
|
Borsa Italiana
| 1IOVA | End-of-day quote |
Last Transcript: Iovance Biotherapeutics, Inc.
| 1 day | -4.22% | ||
| 1 week | +26.20% | ||
| Current month | +26.57% | ||
| 1 month | +40.06% | ||
| 3 months | +155.75% | ||
| 6 months | +157.92% | ||
| Current year | +270.43% |
| 1 week | 7.34 |  | 9.12 |
| 1 month | 6 | | 9.12 |
| Current year | 1.93 | | 9.12 |
| 1 year | 1.59 | | 9.12 |
| 3 years | 1.43 | | 16.85 |
| 5 years | 1.43 | | 23.91 |
| 10 years | 1.43 | | 43.46 |
| Manager | Title | Age | Since |
|---|---|---|---|
Frederick Vogt
CEO | Chief Executive Officer | 52 | 2021-06-17 |
Corleen Roche
DFI | Director of Finance/CFO | 60 | 2025-08-05 |
Igor Bilinsky
COO | Chief Operating Officer | 53 | 2021-03-14 |
| Director | Title | Age | Since |
|---|---|---|---|
Ryan Maynard
BRD | Director/Board Member | 56 | 2015-02-15 |
Wayne Rothbaum
BRD | Director/Board Member | 58 | 2016-06-06 |
Iain Dukes
CHM | Chairman | 67 | 2016-08-15 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.28% | +26.20% | - | - | 4.54B | |
| -0.65% | +17.09% | +105.77% | +413.32% | 4.56B | |
| +0.05% | +16.34% | +354.77% | +68.72% | 4.54B | |
| -1.06% | -1.88% | +20.67% | +64.82% | 3.26B | |
| -1.04% | +7.28% | +265.06% | +581.67% | 2.81B | |
| +6.41% | +9.31% | -23.34% | -25.36% | 2.14B | |
| +3.01% | +10.14% | +54.41% | - | 1.75B | |
| +0.30% | +7.30% | +30.25% | +46.64% | 1.11B | |
| -5.43% | +5.67% | +139.58% | -31.82% | 1.08B | |
| -3.88% | -5.56% | -10.45% | +64.93% | 594M | |
| Average | -0.66% | +8.62% | +104.08% | +147.86% | 2.43B | |
| Weighted average by Cap. | -0.69% | +11.55% | +143.22% | +201.19% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 402M 350M 331M 300M 563M 38.53B 565M 3.96B 1.53B 19.59B 1.51B 1.47B 63.03B | 557M 486M 459M 417M 781M 53.49B 784M 5.5B 2.12B 27.19B 2.09B 2.05B 87.5B |
| Net income | -213M -185M -175M -159M -298M -20.41B -299M -2.1B -810M -10.38B -799M -781M -33.39B | -109M -94.68M -89.4M -81.18M -152M -10.42B -153M -1.07B -413M -5.3B -408M -399M -17.04B |
| Net Debt | -264M -231M -218M -198M -370M -25.37B -372M -2.61B -1.01B -12.9B -993M -971M -41.5B | -276M -240M -227M -206M -386M -26.45B -388M -2.72B -1.05B -13.45B -1.04B -1.01B -43.26B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-18 | €8.670 | -4.93% | 0 |
| 26-09-17 | €9.120 | +13.15% | 1,520 |
| 26-09-16 | €8.060 | -0.37% | 0 |
| 26-09-15 | €8.090 | +10.22% | 300 |
| 26-09-14 | €7.340 | +6.84% | 0 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- IOVA Stock
- 2LB Stock
Select your edition
All financial news and data tailored to specific country editions
